Iron Wolf Capital invests in Self.co to support its growth in advanced diagnostics

Baltic venture capital continues backing startups with global ambition. The latest example: Iron Wolf Capital has invested in Self.co to support the growth of its allergy and food intolerance diagnostics platform and power expansion across Europe, alongside continued growth in Lithuania and Poland. 

The round totals €2.56M, with €1.2M invested by Iron Wolf Capital alongside Coinvest Capital, NGL Ventures, and several business angels. Self.co combines advanced molecular testing with a digital platform that delivers AI-powered, personalised health insights, and has also secured a €1.36M Innovation Agency grant to further develop its technology and clinical capabilities. 

WALLESS team advised Iron Wolf Capital on the investment, with Partner Andrius Ivanauskas and Associate Reda Stalioraitytė providing the transactional support, and Associate Partner Guoda Šileikaitė, Senior Associate Dovilė Jakimonytė, Associate Ieva Šmigelskaite advising on medtech, IP and GDPR regulatory matters.